Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors

Valentina Svicher, Tobias Sing, Maria Mercedes Santoro, Federica Forbici, Fátima Rodríguez-Barrios, Ada Bertoli, Niko Beerenwinkel, Maria Concetta Bellocchi, Federigo Gago, Antonella D Arminio Monforte, Andrea Antinori, Thomas Lengauer, Francesca Ceccherini-Silberstein, Carlo Federico Perno

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

We characterized 16 additional mutations in human immunodeficiency virus type 1 (HTV-1) reverse transcriptase (RT) whose role in drug resistance is still unknown by analyzing 1,906 plasma-derived HIV-1 subtype B pol sequences from 551 drug-naive patients and 1,355 nucleoside RT inhibitor (NRTI)-treated patients. Twelve mutations positively associated with NRTI treatment strongly correlated both in pairs and in clusters with known NRTI resistance mutations on divergent evolutionary pathways. In particular, T39A, K43E/Q, K122E, E203K, and H208Y clustered with the nucleoside analogue mutation 1 cluster (NAM1;M41L+L210W+T215Y). Their copresence in this cluster was associated with an increase in thymidine analogue resistance. Moreover, treatment failure in the presence of K43E, K122E, or H208Y was significantly associated with higher viremia and lower CD4 cell count. Differently, D218E clustered with the NAM2 pathway (D67N+K70R+K219Q+T215F), and its presence in this cluster determined an increase in zidovudine resistance. In contrast, three mutations (V35I, I50V, and R83K) negatively associated with NRTI treatment showed negative correlations with NRTI resistance mutations and were associated with increased susceptibility to specific NRTIs. In particular, I50V negatively correlated with the lamivudine-selected mutation M184V and was associated with a decrease in M184V/lamivudine resistance, whereas R83K negatively correlated with both NAM1 and NAM2 clusters and was associated with a decrease in thymidine analogue resistance. Finally, the association pattern of the F214L polymorphism revealed its propensity for the NAM2 pathway and its strong negative association with the NAM1 pathway. Our study provides evidence of novel RT mutational patterns that regulate positively and/or negatively NRT1 resistance and strongly suggests that other mutations beyond those currently known to confer resistance should be considered for improved prediction of clinical response to antiretroviral drugs.

Original languageEnglish
Pages (from-to)7186-7198
Number of pages13
JournalJournal of Virology
Volume80
Issue number14
DOIs
Publication statusPublished - Jul 2006

Fingerprint

RNA-directed DNA polymerase
nucleosides
Human immunodeficiency virus 1
Nucleosides
HIV-1
mutation
Mutation
Lamivudine
RNA-Directed DNA Polymerase
thymidine
Thymidine
Reverse Transcriptase Inhibitors
Human immunodeficiency virus 1 reverse transcriptase
Zidovudine
Viremia
viremia
drug resistance
CD4 Lymphocyte Count
Treatment Failure
Drug Resistance

ASJC Scopus subject areas

  • Immunology

Cite this

Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. / Svicher, Valentina; Sing, Tobias; Santoro, Maria Mercedes; Forbici, Federica; Rodríguez-Barrios, Fátima; Bertoli, Ada; Beerenwinkel, Niko; Bellocchi, Maria Concetta; Gago, Federigo; Monforte, Antonella D Arminio; Antinori, Andrea; Lengauer, Thomas; Ceccherini-Silberstein, Francesca; Perno, Carlo Federico.

In: Journal of Virology, Vol. 80, No. 14, 07.2006, p. 7186-7198.

Research output: Contribution to journalArticle

Svicher, V, Sing, T, Santoro, MM, Forbici, F, Rodríguez-Barrios, F, Bertoli, A, Beerenwinkel, N, Bellocchi, MC, Gago, F, Monforte, ADA, Antinori, A, Lengauer, T, Ceccherini-Silberstein, F & Perno, CF 2006, 'Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors', Journal of Virology, vol. 80, no. 14, pp. 7186-7198. https://doi.org/10.1128/JVI.02084-05
Svicher, Valentina ; Sing, Tobias ; Santoro, Maria Mercedes ; Forbici, Federica ; Rodríguez-Barrios, Fátima ; Bertoli, Ada ; Beerenwinkel, Niko ; Bellocchi, Maria Concetta ; Gago, Federigo ; Monforte, Antonella D Arminio ; Antinori, Andrea ; Lengauer, Thomas ; Ceccherini-Silberstein, Francesca ; Perno, Carlo Federico. / Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. In: Journal of Virology. 2006 ; Vol. 80, No. 14. pp. 7186-7198.
@article{8e58dd379dc043e7a6dce6d1c7a13a01,
title = "Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors",
abstract = "We characterized 16 additional mutations in human immunodeficiency virus type 1 (HTV-1) reverse transcriptase (RT) whose role in drug resistance is still unknown by analyzing 1,906 plasma-derived HIV-1 subtype B pol sequences from 551 drug-naive patients and 1,355 nucleoside RT inhibitor (NRTI)-treated patients. Twelve mutations positively associated with NRTI treatment strongly correlated both in pairs and in clusters with known NRTI resistance mutations on divergent evolutionary pathways. In particular, T39A, K43E/Q, K122E, E203K, and H208Y clustered with the nucleoside analogue mutation 1 cluster (NAM1;M41L+L210W+T215Y). Their copresence in this cluster was associated with an increase in thymidine analogue resistance. Moreover, treatment failure in the presence of K43E, K122E, or H208Y was significantly associated with higher viremia and lower CD4 cell count. Differently, D218E clustered with the NAM2 pathway (D67N+K70R+K219Q+T215F), and its presence in this cluster determined an increase in zidovudine resistance. In contrast, three mutations (V35I, I50V, and R83K) negatively associated with NRTI treatment showed negative correlations with NRTI resistance mutations and were associated with increased susceptibility to specific NRTIs. In particular, I50V negatively correlated with the lamivudine-selected mutation M184V and was associated with a decrease in M184V/lamivudine resistance, whereas R83K negatively correlated with both NAM1 and NAM2 clusters and was associated with a decrease in thymidine analogue resistance. Finally, the association pattern of the F214L polymorphism revealed its propensity for the NAM2 pathway and its strong negative association with the NAM1 pathway. Our study provides evidence of novel RT mutational patterns that regulate positively and/or negatively NRT1 resistance and strongly suggests that other mutations beyond those currently known to confer resistance should be considered for improved prediction of clinical response to antiretroviral drugs.",
author = "Valentina Svicher and Tobias Sing and Santoro, {Maria Mercedes} and Federica Forbici and F{\'a}tima Rodr{\'i}guez-Barrios and Ada Bertoli and Niko Beerenwinkel and Bellocchi, {Maria Concetta} and Federigo Gago and Monforte, {Antonella D Arminio} and Andrea Antinori and Thomas Lengauer and Francesca Ceccherini-Silberstein and Perno, {Carlo Federico}",
year = "2006",
month = "7",
doi = "10.1128/JVI.02084-05",
language = "English",
volume = "80",
pages = "7186--7198",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "14",

}

TY - JOUR

T1 - Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors

AU - Svicher, Valentina

AU - Sing, Tobias

AU - Santoro, Maria Mercedes

AU - Forbici, Federica

AU - Rodríguez-Barrios, Fátima

AU - Bertoli, Ada

AU - Beerenwinkel, Niko

AU - Bellocchi, Maria Concetta

AU - Gago, Federigo

AU - Monforte, Antonella D Arminio

AU - Antinori, Andrea

AU - Lengauer, Thomas

AU - Ceccherini-Silberstein, Francesca

AU - Perno, Carlo Federico

PY - 2006/7

Y1 - 2006/7

N2 - We characterized 16 additional mutations in human immunodeficiency virus type 1 (HTV-1) reverse transcriptase (RT) whose role in drug resistance is still unknown by analyzing 1,906 plasma-derived HIV-1 subtype B pol sequences from 551 drug-naive patients and 1,355 nucleoside RT inhibitor (NRTI)-treated patients. Twelve mutations positively associated with NRTI treatment strongly correlated both in pairs and in clusters with known NRTI resistance mutations on divergent evolutionary pathways. In particular, T39A, K43E/Q, K122E, E203K, and H208Y clustered with the nucleoside analogue mutation 1 cluster (NAM1;M41L+L210W+T215Y). Their copresence in this cluster was associated with an increase in thymidine analogue resistance. Moreover, treatment failure in the presence of K43E, K122E, or H208Y was significantly associated with higher viremia and lower CD4 cell count. Differently, D218E clustered with the NAM2 pathway (D67N+K70R+K219Q+T215F), and its presence in this cluster determined an increase in zidovudine resistance. In contrast, three mutations (V35I, I50V, and R83K) negatively associated with NRTI treatment showed negative correlations with NRTI resistance mutations and were associated with increased susceptibility to specific NRTIs. In particular, I50V negatively correlated with the lamivudine-selected mutation M184V and was associated with a decrease in M184V/lamivudine resistance, whereas R83K negatively correlated with both NAM1 and NAM2 clusters and was associated with a decrease in thymidine analogue resistance. Finally, the association pattern of the F214L polymorphism revealed its propensity for the NAM2 pathway and its strong negative association with the NAM1 pathway. Our study provides evidence of novel RT mutational patterns that regulate positively and/or negatively NRT1 resistance and strongly suggests that other mutations beyond those currently known to confer resistance should be considered for improved prediction of clinical response to antiretroviral drugs.

AB - We characterized 16 additional mutations in human immunodeficiency virus type 1 (HTV-1) reverse transcriptase (RT) whose role in drug resistance is still unknown by analyzing 1,906 plasma-derived HIV-1 subtype B pol sequences from 551 drug-naive patients and 1,355 nucleoside RT inhibitor (NRTI)-treated patients. Twelve mutations positively associated with NRTI treatment strongly correlated both in pairs and in clusters with known NRTI resistance mutations on divergent evolutionary pathways. In particular, T39A, K43E/Q, K122E, E203K, and H208Y clustered with the nucleoside analogue mutation 1 cluster (NAM1;M41L+L210W+T215Y). Their copresence in this cluster was associated with an increase in thymidine analogue resistance. Moreover, treatment failure in the presence of K43E, K122E, or H208Y was significantly associated with higher viremia and lower CD4 cell count. Differently, D218E clustered with the NAM2 pathway (D67N+K70R+K219Q+T215F), and its presence in this cluster determined an increase in zidovudine resistance. In contrast, three mutations (V35I, I50V, and R83K) negatively associated with NRTI treatment showed negative correlations with NRTI resistance mutations and were associated with increased susceptibility to specific NRTIs. In particular, I50V negatively correlated with the lamivudine-selected mutation M184V and was associated with a decrease in M184V/lamivudine resistance, whereas R83K negatively correlated with both NAM1 and NAM2 clusters and was associated with a decrease in thymidine analogue resistance. Finally, the association pattern of the F214L polymorphism revealed its propensity for the NAM2 pathway and its strong negative association with the NAM1 pathway. Our study provides evidence of novel RT mutational patterns that regulate positively and/or negatively NRT1 resistance and strongly suggests that other mutations beyond those currently known to confer resistance should be considered for improved prediction of clinical response to antiretroviral drugs.

UR - http://www.scopus.com/inward/record.url?scp=33745781478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745781478&partnerID=8YFLogxK

U2 - 10.1128/JVI.02084-05

DO - 10.1128/JVI.02084-05

M3 - Article

VL - 80

SP - 7186

EP - 7198

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 14

ER -